Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Flaherty

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Oncotarget|October 22, 2021
Correction: Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.
Oncotarget|September 8, 2016
Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.
Progress in Molecular Biology and Translational Science|August 25, 2022
Evolution of biomarker research in autoimmunity conditions for health professionals and clinical practiceArthur Silverstein, Anton Dudaev, Maria Studneva, et al.
Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in GliomasShengnan Yu, Shiyou Wei, Milan Savani, et al.
Nature Medicine|June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
Nature Communications|April 4, 2019
Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5<sup>-/-</sup> miceYan Li, Roberto Tinoco, Lisa Elmén, et al.
Nature Communications|September 21, 2017
Tumor-associated B-cells induce tumor heterogeneity and therapy resistanceRajasekharan Somasundaram, Gao Zhang, Mizuho Fukunaga-Kalabis, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Oncotarget|October 22, 2021
Correction: Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.
Oncotarget|September 8, 2016
Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.
Progress in Molecular Biology and Translational Science|August 25, 2022
Evolution of biomarker research in autoimmunity conditions for health professionals and clinical practiceArthur Silverstein, Anton Dudaev, Maria Studneva, et al.
Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in GliomasShengnan Yu, Shiyou Wei, Milan Savani, et al.
Nature Medicine|June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
Nature Communications|April 4, 2019
Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5<sup>-/-</sup> miceYan Li, Roberto Tinoco, Lisa Elmén, et al.
Nature Communications|September 21, 2017
Tumor-associated B-cells induce tumor heterogeneity and therapy resistanceRajasekharan Somasundaram, Gao Zhang, Mizuho Fukunaga-Kalabis, et al.
Pageof 7